Research Topics
| Jerry AvornSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
'Bench to behavior': translating comparative effectiveness research into improved clinical practiceJerry Avorn
Harvard Medical School, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Health Aff (Millwood) 29:1891-900. 2010..Such strategies can lead to policies that could encourage the uptake of new comparative effectiveness data and encourage their translation into better clinical practice...
Adverse Drug Reactions in Elderly People: A substantial cause of preventable illnessJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02120, USA
BMJ 336:956-7. 2008
Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetesWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Am J Kidney Dis 46:1080-7. 2005..However, little is known about the adequacy of adherence to these guidelines in elderly patients with diabetes and predictors of such appropriate ACE-inhibitor or ARB use...- Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy labelWilliam H Shrank
Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street Suite 3030, Boston, MA 02120, USA
J Gen Intern Med 24:570-8. 2009..A new prescription medication labeling system was implemented by Target pharmacies in May 2005 and aimed to improve readability and understanding... - Patient, physician, and payment predictors of statin adherenceDavid C Chan
Department of Medicine, Division of General Internal Medicine, Brigham and Women s Hospital, Boston, MA, USA
Med Care 48:196-202. 2010..Although many patient, physician, and payment predictors of adherence have been described, knowledge of their relative strength and overall ability to explain adherence is limited... - Improved comorbidity adjustment for predicting mortality in Medicare populationsSebastian Schneeweiss
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Health Serv Res 38:1103-20. 2003..80. CONCLUSIONS: We conclude that in epidemiologic studies of the elderly, a modified diagnosis-based score using empirically derived weights provides improved adjustment for comorbidity and enhances the validity of findings... - Warnings without guidance: patient responses to an FDA warning about ezetimibeWilliam H Shrank
Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston 02120, USA
Med Care 50:479-84. 2012..We investigated the proportion of patients who discontinued therapy and switched to a clinically appropriate alternative after the FDA communication... - The association between statin use and outcomes potentially attributable to an unhealthy lifestyle in older adultsAmanda R Patrick
Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Value Health 14:513-20. 2011.... - Full coverage for preventive medications after myocardial infarctionNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
N Engl J Med 365:2088-97. 2011..Adherence to medications that are prescribed after myocardial infarction is poor. Eliminating out-of-pocket costs may increase adherence and improve outcomes... - At Pitney Bowes, value-based insurance design cut copayments and increased drug adherenceNiteesh K Choudhry
Harvard Medical School, USA
Health Aff (Millwood) 29:1995-2001. 2010..Our study thus provides an empirical basis for the use of this approach to improve the quality of health care... - Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillationSebastian Schneeweiss
Department of Medicine, Harvard Medical School, Boston, MA, USA
Circ Cardiovasc Qual Outcomes 5:480-6. 2012..We sought to compare the efficacy and safety of the 3 new agents based on data from their published warfarin-controlled randomized trials, using the method of adjusted indirect comparisons... - Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implicationsNihar R Desai
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Am J Med 125:302.e1-7. 2012..We aimed to evaluate temporal trends in the use of specific drugs for the initial management of type 2 diabetes and to estimate the economic consequences of non-recommended care... - The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustrationAmanda R Patrick
Division of Pharmacoepidemiology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Pharmacoepidemiol Drug Saf 20:551-9. 2011.... - Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?Daniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Med 115:715-20. 2003..We examined the relative effects of patient risk factors for gastrointestinal toxicity, other patient characteristics, and physician prescribing preferences on the decision to prescribe a selective COX-2 inhibitor... - Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarctionKouta Ito
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Health Serv Res 47:2097-117. 2012..To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients... - The prevalence and cost of unapproved uses of top-selling orphan drugsAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 7:e31894. 2012..However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales... - Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary studyGladys Ting
Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Arthritis Res Ther 10:R95. 2008.... - Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapiesNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
Am Heart J 156:31-6. 2008..Removing patient out-of-pocket drug costs may increase adherence, improve clinical outcomes, and even reduce overall health costs for high-risk patients. The existing data are inadequate to assess whether this strategy is effective... - Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groupsDaniel H Solomon
Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
Arthritis Rheum 59:1097-104. 2008..There is substantial concern regarding the potential cardiovascular adverse effects of selective coxibs and nonselective NSAIDs, but many patients with arthritis experience important clinical benefits from these agents... - Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?William H Shrank
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Med Care 47:319-25. 2009..Insurers and policymakers strive to stimulate more cost-effective prescribing and, increasingly, are educating beneficiaries about generics... - Trouble getting started: predictors of primary medication nonadherenceMichael A Fischer
Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Am J Med 124:1081.e9-22. 2011..The advent of electronic prescribing (e-prescribing) systems provides the opportunity to track initial prescriptions and identify nonadherence that may have previously been undetected... - High-dimensional propensity score adjustment in studies of treatment effects using health care claims dataSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Epidemiology 20:512-22. 2009..Here, we develop and test an algorithm that empirically identifies candidate covariates, prioritizes covariates, and integrates them into a propensity-score-based confounder adjustment model... - NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxibSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 021205, USA
Pharmacoepidemiol Drug Saf 18:1134-42. 2009.... - The implications of therapeutic complexity on adherence to cardiovascular medicationsNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
Arch Intern Med 171:814-22. 2011..Our objective was to estimate the extent of prescribing and filling complexity in patients prescribed a cardiovascular medication and to evaluate its association with adherence... - Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndromeJeremy A Rassen
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
Circulation 120:2322-9. 2009..Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk... - Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritisDaniel H Solomon
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Arthritis Rheum 54:3790-8. 2006..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA... - Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysisNiteesh K Choudhry
Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
Health Aff (Millwood) 26:186-94. 2007..Our analysis suggests that covering combination therapy for such patients will save both lives and money... - Keeping science on top in drug evaluationJerry Avorn
Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston, USA
N Engl J Med 357:633-5. 2007 - Identification of individuals with CKD from Medicare claims data: a validation studyWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Am J Kidney Dis 46:225-32. 2005..The validity of this approach to identify patients with CKD has not been sufficiently studied... - Relationship between COX-2 specific inhibitors and hypertensionDaniel H Solomon
Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
Hypertension 44:140-5. 2004..1; 95% CI, 1.0 to 4.3). In this retrospective case-control study of patients aged > or =65 years, rofecoxib use was associated with an increased relative risk of new onset hypertension; this was not seen in patients taking celecoxib... - Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adultsDaniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, Mass 02120, USA
Circulation 109:2068-73. 2004..We studied the relative risk of acute myocardial infarction (AMI) among users of celecoxib, rofecoxib, and NSAIDs in Medicare beneficiaries with a comprehensive drug benefit... - The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditionsWilliam H Shrank
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
Arch Intern Med 166:332-7. 2006..We studied whether patients enrolled in such plans who receive generic or preferred brand-name agents when initiating chronic therapy were more adherent to treatment than those who received nonpreferred brand-name medications... - Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatmentsSebastian Schneeweiss
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
BMC Med Res Methodol 12:180. 2012..Adjusting for laboratory test results may result in better confounding control when added to administrative claims data in the study of treatment effects. However, missing values can arise through several mechanisms... - A randomized study of how physicians interpret research funding disclosuresAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
N Engl J Med 367:1119-27. 2012..The effects of clinical-trial funding on the interpretation of trial results are poorly understood. We examined how such support affects physicians' reactions to trials with a high, medium, or low level of methodologic rigor... - Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examplesPeter M Wahl
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02120, USA
Drug Saf 35:407-16. 2012..Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signals due to chance and bias... - Comparative safety of antipsychotic medications in nursing home residentsKrista F Huybrechts
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
J Am Geriatr Soc 60:420-9. 2012..To compare the risk of major medical events in nursing home residents newly initiated on conventional or atypical antipsychotic medications (APMs)... - Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trialWilliam H Shrank
Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
Am Heart J 157:613-9. 2009..Highly effective generic cardiovascular medications are frequently underused, leading to greater overall drug costs and cost-related nonadherence... - Correlations of nursing home characteristics with prescription of osteoporosis medicationsSeema Parikh
Harvard Medical School, Boston, MA, USA
Bone 48:1164-8. 2011..NH characteristics have been associated with prescription of some medications. We examined associations of NH-level characteristics with osteoporosis treatment in elderly patients admitted to a NH after a fracture... - The epidemiology of prescriptions abandoned at the pharmacyWilliam H Shrank
Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
Ann Intern Med 153:633-40. 2010..Understanding the epidemiology and correlates of prescription abandonment may have an important effect on health care quality... - Anticonvulsant medications and the risk of suicide, attempted suicide, or violent deathElisabetta Patorno
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120, USA
JAMA 303:1401-9. 2010..The decision was based on a meta-analysis not sufficiently large to investigate individual drugs... - The consequences of requesting "dispense as written"William H Shrank
Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Am J Med 124:309-17. 2011..Patients also can make these requests. Little is known about the frequency and correlates of dispense as written requests or their association with medication filling... - Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysisAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
Drugs 70:605-21. 2010..In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs... - Propranolol and the risk of hospitalized myopathy: translating chemical genomics findings into population-level hypothesesSoko Setoguchi
Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Am Heart J 159:428-33. 2010..We tested this hypothesis in a large population to assess whether (1) propranolol use is associated with an increased risk of myopathy and (2) the concurrent use of propranolol with a statin may further increase risk of myopathy... - High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in PennsylvaniaJennifer M Polinski
Brigham and Women s Hospital, Boston, Massachusetts, USA
Int Q Community Health Educ 29:223-40. 2008..We found several correlates of readiness to undergo BMD screening that may be used to design effective interventions... - Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plansMichael A Fischer
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA
Health Serv Res 38:1051-63. 2003..Further savings could be realized if lowest available prices were used nationwide. Concentrating on specific agents may be a productive way to address the unrealized savings... - Compliance with osteoporosis medicationsDaniel H Solomon
Divisions of Pharmacoepidemiology, Brigham and Women s Hospital, Boston, MA 02120, USA
Arch Intern Med 165:2414-9. 2005..This study was undertaken to assess the level and determinants of compliance with drugs prescribed for osteoporosis... - The costs and benefits of enhanced depression care to employersPhilip S Wang
Department of Psychiatry, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, USA
Arch Gen Psychiatry 63:1345-53. 2006..Although outreach and enhanced treatment interventions improve depression outcomes, uptake has been poor in part because purchasers lack information on their return on investment... - Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosuresAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 9:e1001280. 2012..It is unknown whether physicians and scientists who have such conflicts of interest adequately disclose such relationships in the scientific publications they author... - Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trialDaniel H Solomon
Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Arch Intern Med 172:477-83. 2012..We examined the effectiveness of a telephone-based counseling program rooted in motivational interviewing to improve adherence to a medication regimen for osteoporosis... - False Claims Act prosecution did not deter off-label drug use in the case of neurontinAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
Health Aff (Millwood) 30:2318-27. 2011.... - Drug warnings that can cause fits--communicating risks in a data-poor environmentJerry Avorn
Harvard Medical School, and Brigham and Women's Hospital, Boston, USA
N Engl J Med 359:991-4. 2008 - Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillationAmanda R Patrick
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
Circ Cardiovasc Qual Outcomes 2:429-36. 2009..However, the effectiveness of genotyping in improving anticoagulation control and reducing major bleeding has not yet been compellingly demonstrated. Genotyping currently costs $400 to $550... - Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesJeremy A Rassen
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Pharmacoepidemiol Drug Saf 19:848-57. 2010..We sought to create a method to conduct pooled analyses while keeping information private and allowing for full confounder adjustment... - A combined comorbidity score predicted mortality in elderly patients better than existing scoresJoshua J Gagne
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
J Clin Epidemiol 64:749-59. 2011..To develop and validate a single numerical comorbidity score for predicting short- and long-term mortality, by combining conditions in the Charlson and Elixhauser measures... - Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritisSoko Setoguchi
Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
Am Heart J 156:336-41. 2008..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA... - Nephrologist care and mortality in patients with chronic renal insufficiencyJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Arch Intern Med 162:2002-6. 2002..These findings need to be confirmed in younger and less indigent patients as well... - Dopamine antagonists and the development of breast cancerPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115, USA
Arch Gen Psychiatry 59:1147-54. 2002..In light of the small hazards and the possibility of residual confounding, these findings should lead to follow-up investigations but not to changes in treatment strategies... - Nonsteroidal anti-inflammatory drug use and acute myocardial infarctionDaniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Arch Intern Med 162:1099-104. 2002..Although aspirin has been shown to protect patients from acute myocardial infarction (AMI), the effect of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is not clear... - Prescription opioid use among older adults with arthritis or low back painDaniel H Solomon
Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Ste, 3030, Boston, MA 02120, USA
Arthritis Rheum 55:35-41. 2006..To examine patterns of chronic opioid use in selected groups with arthritis and low back pain and compare them with patterns among persons with ischemic heart disease... - Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitorsMichael A Fischer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
N Engl J Med 351:2187-94. 2004..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries... - Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of ageSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 100:1061-7. 2007..The underuse of statins and BBs was marked in black patients and did not improve over time... - Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritisSoko Setoguchi
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
Arthritis Rheum 54:2757-64. 2006..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA... - Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation studyTIL STURMER
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Am J Epidemiol 172:843-54. 2010..Increasing validity based on PS trimming may be a unique advantage of PS's over conventional outcome models... - Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy reviewMichael A Fischer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
Med Care 44:658-63. 2006..However, the evidence base for the prior authorization criteria has not been examined previously... - Highlights and a hidden hazard--the FDA's new labeling regulationsJerry Avorn
Harvard Medical School and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston, USA
N Engl J Med 354:2409-11. 2006 - Pharmacoepidemiology and rheumatic diseases: 2001-2002Daniel H Solomon
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Curr Opin Rheumatol 15:122-6. 2003.... - Angiotensin inhibition after myocardial infarction: does drug class matter?Wolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02120, USA
J Gen Intern Med 21:1242-7. 2006..Little is known about their relative use after MI in typical care settings, and about their relative effectiveness outside the clinical trial setting... - Torcetrapib and atorvastatin--should marketing drive the research agenda?Jerry Avorn
Harvard Medical School, Boston, USA
N Engl J Med 352:2573-6. 2005 - Osteoporosis action: design of the healthy bones project trialDaniel H Solomon
Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, USA
Contemp Clin Trials 26:78-94. 2005..All outcomes will be analyzed using random effects models accounting for clustering of subjects within physicians' practices... - Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsYuka Kiyota
Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, Mass USA
Am Heart J 148:99-104. 2004..1% vs 94.6%, P <.001). CONCLUSIONS: In this study, we observed high positive predictive values for a Medicare claims-based diagnosis of AMI and a diagnosis based on structured hospital record review... - Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancerAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120, USA
JAMA 305:2320-6. 2011..Orphan products constitute most new drug approvals in oncology, but safety and efficacy questions have emerged about some of these agents... - Conflict of interest in oncology publications: a survey of disclosure policies and statementsAaron S Kesselheim
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
Cancer 118:188-95. 2012..The authors sought to define current disclosure policies and how they relate to disclosure statements provided by authors in major oncology journals... - The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levelsNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
J Am Coll Cardiol 57:784-91. 2011..We sought to evaluate the cost-effectiveness of applying the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial results into clinical practice... - Using patent data to assess the value of pharmaceutical innovationAaron S Kesselheim
Department of Health Policy and Management, Harvard School of Public Health, Harvard Medical School, USA
J Law Med Ethics 37:176-83. 2009.... - The economic consequences of non-evidence-based clopidogrel useNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
Am Heart J 155:904-9. 2008..However, little is known about the appropriateness of that use. Overuse of clopidogrel could have important implications for health care quality and drug expenditures... - An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomesWilliam H Shrank
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
Med Care 47:1031-5. 2009..A new prescription medication labeling system was implemented by Target pharmacies in May 2005 and aimed to improve health outcomes... - Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysisNiteesh K Choudhry
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
Ann Pharmacother 42:1563-72. 2008..Because of superior safety and lower cost, rate control is now the recommended strategy for the management of most elderly, high-risk AF patients... - Balancing the cost and value of medications: the dilemma facing cliniciansJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, USA
Pharmacoeconomics 20:67-72. 2002.... - Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin useM Alan Brookhart
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
Arch Intern Med 167:847-52. 2007.... - Risk of death in elderly users of conventional vs. atypical antipsychotic medicationsPhilip S Wang
Department of Psychiatry, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
N Engl J Med 353:2335-41. 2005..However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known... - Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic modelRoy H Perlis
Pharmacogenomics Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 25:427-34. 2005..More consistent reporting of test parameters such as sensitivity and specificity would greatly facilitate assessment of future pharmacogenetic studies... - Part "D" for "defective"--the Medicare drug-benefit chaosJerry Avorn
Harvard Medical School, Boston, USA
N Engl J Med 354:1339-41. 2006 - A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsTIL STURMER
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
J Clin Epidemiol 59:437-47. 2006..Such analyses have been proposed to address confounding by indication, but there is little empirical evidence that they achieve better control than conventional multivariate outcome modeling... - Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trialJerry Avorn
Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Control Clin Trials 23:757-73. 2002.... - Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based studySebastian Schneeweiss
Department of Medical Informatics, Biometry and Epidemiology, Pharmacoepidemiology Research Group, Ludwig Maximilians University, Munich, Germany
Eur J Clin Pharmacol 58:285-91. 2002..To estimate incidence rates of drug-related hospitalizations (DRHs) in a longitudinal population-based study with prospective event assessment... - Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgeryWolfgang C Winkelmayer
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Am J Kidney Dis 41:84-9. 2003..The aim of the study is to define the role of chronic kidney disease (CKD) as a risk factor for postoperative bleeding in patients undergoing coronary artery bypass graft (CABG) surgery... - The rise and fall of Natrecor for congestive heart failure: implications for drug policyAaron S Kesselheim
Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts, USA
Health Aff (Millwood) 25:1095-102. 2006..Based on the nesiritide experience, we suggest several ways to improve policies for drug approval, postmarketing surveillance, and drug utilization... - Underuse of osteoporosis medications in elderly patients with fracturesDaniel H Solomon
Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, Massachusetts 02120, USA
Am J Med 115:398-400. 2003 - Hetastarch and bleeding complications after coronary artery surgeryJerry Avorn
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Chest 124:1437-42. 2003..To determine whether intraoperative HES use is associated with an increased risk of postoperative bleeding following coronary artery bypass graft (CABG) surgery... - Use of the case-crossover design to study prolonged drug exposures and insidious outcomesPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Ann Epidemiol 14:296-303. 2004..We investigated whether case-crossover methods can be used to study prolonged exposures and insidious outcomes... - Economic implications of evidence-based prescribing for hypertension: can better care cost less?Michael A Fischer
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02120, USA
JAMA 291:1850-6. 2004..Suboptimal prescribing patterns contribute to the high cost of medications for elderly patients as well as the difficulty in providing affordable prescription drug benefits for older Americans... - Pharmacoepidemiology and "in silico" drug evaluation: is there common ground?TIL STURMER
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Boston, MA 02120, USA
J Clin Epidemiol 61:205-6. 2008 - Design of cluster-randomized trials of quality improvement interventions aimed at medical care providersRobert J Glynn
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
Med Care 45:S38-43. 2007..Such trials are frequently embedded in health care systems with available automated records, which can be used to enhance the design of the trial... - How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptionsPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Pharmacoepidemiol Drug Saf 13:11-9. 2004..Although self-reports are often the only means available in routine practice, their accuracy and agreement with other data sources remain questionable... - Suboptimal antidepressant use in the elderlyPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
J Clin Psychopharmacol 25:118-26. 2005..Suboptimal antidepressant use remains common in the elderly, especially the use of inadequately intensive regimens. Interventions are needed to improve the quality and outcomes of antidepressant use in this vulnerable population... - Racial differences in screening for prostate cancer in the elderlyTimothy Gilligan
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Arch Intern Med 164:1858-64. 2004..Low screening rates among black men may contribute to these disparities, but there are few data on racial differences in prostate cancer screening... - Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factorsPhilip S Wang
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School Boston, Mass 02115, USA
J Gen Intern Med 17:504-11. 2002..Addressing the epidemic of poor compliance with antihypertensive medications will require identifying factors associated with poor adherence, including modifiable psychosocial and behavioral characteristics of patients... - Coagulation and adulteration--building on science and policy lessons from 1905Jerry Avorn
Harvard Medical School, Harvard Interfaculty Initiative on Medications and Society, and Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Boston, USA
N Engl J Med 358:2429-31. 2008 - Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic reviewKirsten E Austad
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 8:e1001037. 2011..Physicians' attitudes towards the industry can form early in their careers, but little is known about this key stage of development... - The effect of altitude on dosing and response to erythropoietin in ESRDM Alan Brookhart
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
J Am Soc Nephrol 19:1389-95. 2008..Furthermore, resistance to EPO decreased with elevation. Our results suggest that ESRD patients living at high altitude either increase endogenous EPO production or respond better to endogenous and exogenous EPO... - Pharmacological management of osteoporosis in nursing home populations: a systematic reviewSeema Parikh
Brigham and Womens Hospital and Harvard Medical School, Boston, Massachusetts, USA
J Am Geriatr Soc 57:327-34. 2009..Prescribing for elderly NH patients is difficult, considering the risk:benefit ratio and issues of longevity, but these medications may be underused in the NH environment...